Sign in Subscribe

article

A collection of 624 issues

Five-year colonoscopy surveillance may be as safe as three-year intervals after high-risk polyp removal

Skip to content The CRC Digest ▪ SCREENING Five-year colonoscopy surveillance may be as safe as three-year intervals after high-risk polyp removal A European randomized trial compared colonoscopy at 5 years versus 3 years after removal of high-risk adenomas (≥10 mm, high-grade dysplasia, villous features, or 3–10 adenomas), with 10-year

Critical review outlines biomarker-guided treatment selection in metastatic CRC

Skip to content The CRC Digest Critical review outlines biomarker-guided treatment selection in metastatic CRC A structured narrative review separately examines mismatch repair-deficient/MSI-H and microsatellite-stable disease, distinguishing established treatments from investigational strategies based on molecular alterations including BRAF V600E and HER2. (Crit Rev Oncol Hematol) This content is informational

Prospective study examines MSI and CD8+ TILs in neoadjuvant chemotherapy response

Skip to content The CRC Digest Prospective study examines MSI and CD8+ TILs in neoadjuvant chemotherapy response A prospective observational study investigated whether microsatellite instability, CD8+ tumor infiltrating lymphocytes expression, and chemotherapy response are related in colorectal cancer patients receiving neoadjuvant treatment. (Cancer Manag Res) This content is informational only

Oral KRAS G12D inhibitor GFH375 evaluated in phase 1 trial

Skip to content The CRC Digest Oral KRAS G12D inhibitor GFH375 evaluated in phase 1 trial GFH375 targets both GTP-bound and GDP-bound states of KRAS G12D proteins, the most prevalent RAS mutation in solid tumors, in patients with advanced colorectal cancer, pancreatic cancer, and non-small cell lung cancer. (Nat Med)

Phase II trial examines quality of life with panitumumab-based intensified regimen

Skip to content The CRC Digest Phase II trial examines quality of life with panitumumab-based intensified regimen The VOLFI trial analyzed health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with mFOLFOXIRI plus panitumumab versus FOLFOXIRI, noting that anti-EGFR antibodies like panitumumab are associated with a

Screening strategies may not adequately address early-onset CRC burden

Skip to content The CRC Digest Screening strategies may not adequately address early-onset CRC burden A systematic review found uncertainty remains regarding whether current screening strategies adequately address the diagnostic burden of early-onset colorectal cancer, defined as diagnosis before age 50. (Cancer Epidemiol) This content is informational only and does

Study identifies FAIM2 pathway in cancer-associated fibroblasts linked to immune resistance in MSS colorectal cancer

Skip to content The CRC Digest ◇ RESEARCH Study identifies FAIM2 pathway in cancer-associated fibroblasts linked to immune resistance in MSS colorectal cancer Researchers identified Fas apoptotic inhibitory molecule 2 (FAIM2) as a stromal regulator downregulated in microsatellite-stable colorectal cancer, where it inversely correlates with collagen production in cancer-associated fibroblasts and

Phase 1 trial evaluates oral KRAS G12D inhibitor GFH375 in advanced solid tumors

Skip to content The CRC Digest ▸ TREATMENT Phase 1 trial evaluates oral KRAS G12D inhibitor GFH375 in advanced solid tumors A phase 1 dose-escalation trial evaluated GFH375, an oral compound that targets both active and inactive states of KRAS G12D proteins, in patients with advanced solid tumors harboring the KRAS

Meta-analysis shows ctDNA after surgery strongly predicts recurrence risk

Skip to content The CRC Digest ◇ RESEARCH Meta-analysis shows ctDNA after surgery strongly predicts recurrence risk A meta-analysis of seven prospective cohorts found that postoperative circulating tumor DNA positivity was associated with increased recurrence risk (pooled hazard ratio, 7.60; 95% CI, 4.70-12.31) after curative-intent colorectal cancer resection,

Systematic review finds screening gaps in early-onset colorectal cancer despite lowered age thresholds

Skip to content The CRC Digest ▪ SCREENING Systematic review finds screening gaps in early-onset colorectal cancer despite lowered age thresholds A systematic review of population-based screening studies found that current strategies may not adequately address the diagnostic burden of colorectal cancer in adults younger than 50, even as several countries